Specialty Pharma Journal Specialty, Precision & Technology
Today, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes a number of changes that, if finalized, will ensure that Part D Medicare enrollees have access to more affordable prescription drugs and more robust prescription drug coverage at the pharmacy they prefer. The rule also …
Tag Archives: cms
November, 2017
March, 2016
-
11 March
MHA’s Business Summit Reveals Key Trends in the Alternate Site Health Care Industry
FLORHAM PARK, N.J., March 10, 2016 /PRNewswire/ — Managed Health Care Associates, Inc. (MHA), a leading health care services and technology company focused on the alternate site health care provider marketplace, is pleased to announce the key industry trends that emerged from its 13th Annual Business Summit at The Bellagio, Las …
February, 2016
-
4 February
Biosimilars Forum Issues Statement Regarding House Energy & Commerce, Subcommittee on Health Biosimilars Hearing, Launch of New Biosimilars
Washington, DC, February 4, 2016 – The Biosimilars Forum – the nonprofit organization solely dedicated to expanding patient access to biosimilars in the United States – issued the following statement about the Biosimilars hearing before the House Energy and Commerce, Subcommittee on Health and the launch of a new biosimilars education …
December, 2015
-
11 December
Physician Groups Urge Congress to Direct CMS to Adopt Unique Billing Codes for Biosimilars
WASHINGTON, Dec. 9, 2015 /PRNewswire-USNewswire/ — On Wednesday, December 9, 2015, six groups representing a broad spectrum of physicians who prescribe biologics – Alliance for Patient Access, American Association of Clinical Endocrinologists, American College of Rheumatology, American Gastroenterological Association, Biologics Prescribers Collaborative, and Coalition of State Rheumatology Organizations – sent a …
November, 2015
-
4 November
GPhA Says US Biosimilars Reimbursement Rule May Discourage Patient Access
WASHINGTON, DC (October 30, 2015) — The Biosimilars Council, a division of the Generic Pharmaceutical Association (GPhA), is disappointed today by the Centers for Medicare & Medicaid Services’ (CMS) decision to group all biosimilars together under one payment calculation and billing code in Medicare Part B, while using a different …
October, 2015
-
8 October
Biosimilars Forum Applauds Senators Roberts, Carper for Leadership on Proposed Medicare Rule on Biosimilar Coding
Washington, D.C. (October 8, 2015) – The Biosimilars Forum today expressed support for Senators Pat Roberts (R-KS) and Tom Carper (D-DE) as well as 18 additional Senators for their leadership in sending a letter to Andrew Slavitt, Acting Administrator for the Centers for Medicare & Medicaid Services (CMS) regarding the …
July, 2015
-
8 July
CMS Announces New Initiative to Promote Value-Based Home Health Care
The Centers for Medicare & Medicaid Services (CMS) today announced a proposal to launch a new model designed to support greater quality of care among Medicare beneficiaries. The model is included in the CY 2016 Home Health Prospective Payment System proposed rule, which updates payments and requirements for home health …
June, 2015
-
1 June
CMS Shares Medicare Data on Hospital and Physician Utilization
The Centers for Medicare & Medicaid Services (CMS) announced today that it is posting new Medicare data to increase transparency on hospital and physician utilization. The Administration said that it is posting its third annual release of the Medicare hospital utilization and payment data, as well as the second annual …
May, 2015
-
1 May
CMS Reported $103 Billion in Medicare Part D Drug Spend in 2013
In 2013, Medicare spent more than $103 billion on Part D prescriptions, according to new data released by the Centers for Medicare & Medicaid Services (CMS). The new data set contains information from more than one million distinct health care providers who as a group prescribed approximately $103 billion in …
April, 2015
-
7 April
CMS Guidance on Biosimilar Reimbursement is One of Many Expected in 2015
By Kathleen P. Wolff, MBA On Mar. 30, 2015, the Centers for Medicare & Medicaid Services (CMS) issued important new guidance on biosimilar reimbursement. Not only was the guidance itself noteworthy, it comes less than a month from the decision to approve the first biosimilar in the U.S. and is …